# US 10,946,037 B1 · Pharmaceutical composition for the prevention or treatment of nicotine addiction and withdrawal symptoms including miRNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,037 B1
- Document ID: US10946037B1
- Status: Granted
- Kind: B1
- Application number: 16/927,193
- Filed: 2020-07-13
- Granted: 2021-03-16
- Earliest claimed: 2019-10-23
- Assignees: Korea Institute of Science and Technology
- Applicants: Korea Institute of Science and Technology
- Inventors: Heh-In Im; Byung Sun Kim
- Web page: https://patentgrep.com/patent/US10946037B1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 25/34: Tobacco-abuse
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed is a pharmaceutical composition for preventing or treating nicotine addiction or withdrawal symptoms. The pharmaceutical composition includes miR-137 as an active ingredient. Overexpression of miR-137 in an animal model having nicotine addiction or withdrawal symptoms results in relief, prevention or amelioration of the symptoms. Therefore, the use of miR-137 contributes to the prevention or treatment of nicotine addiction or withdrawal symptoms and is expected to be useful for developing relevant therapeutic agents.

## Claims

### Claim 1

A method for screening a candidate for treating nicotine addiction or withdrawal symptoms comprising:
a) treating an animal model having nicotine addiction or withdrawal symptoms with a candidate;
b) measuring the expression level of miR-137 in the animal model treated with the candidate;
c) determining whether the candidate increases the expression level of miR-137 compared to an untreated control; and
d) administering the candidate containing miR-137 to a patient for treating the nicotine addition or the withdrawal symptoms if the candidate increases the expression level of miR-137 compared to the untreated control.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the miR-137 has the sequence set forth in SEQ ID NO: 1.